Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00966251
Recruitment Status :
(The study was stopped because of slow accrual)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subjects aged 18 years and above, both genders.
Histologically or cytologically confirmed Primary Hepatocellular Carcinoma (HCC)
No fibrolamellar subtype HCC
Not eligible for any other systemic anti-neoplastic treatment approved for HCC
Not eligible for Transarterial chemoembolization (TACE ).
No more than 1 prior systemic therapy. Previous TACE or Radiofrequency ablation (RFA) that were used for HCC, are permitted.
Not a candidate for curative surgical resection or liver transplantation
Measurable disease defined by the identification at least 1 measurable lesion by MRI using RECIST criteria. Tumor in area of TACE or RFA must be enlarging post-procedure to be considered measurable disease.
Alpha-fetoprotein (AFP) greater than the upper limit of normal (ULN)
Child's Pugh classification A
ECOG performance status 0-1
Patients progressing to liver failure.
No core biopsy within the past 7 days
Patients who are eligible for Transarterial Chemoembolization (TACE)
Patients on concurrent anti-neoplastic therapy (including interferon)
Patients who have received any systemic anti-neoplastic therapy not approved for the treatment of HCC.
Patients on concurrent steroids, other than those allowed for routine antiemetics, or inhaled steroids